Sanofi, Regeneron Expand Immunology Partnership in $1 Billion Deal

Sanofi (SASY) shares rose 1.4% to €73.65 after announcing an $8B collaboration with Regeneron to co-develop and co-commercialize four new antibodies. The deal includes a $1B upfront payment and up to $7B in milestone payments. Analysts have a Buy rating and a 12-month price target of €94.06, suggesting significant upside from current levels.

Sanofi will pay Regeneron $1B upfront and up to $7B in milestones for four new antibodies under their Dupixent partnership. Sanofi shares rose 2% on the news. The deal aims to strengthen Sanofi's pipeline before Dupixent's patent expiry. Regeneron will lead R&D, while Sanofi handles global sales. Profits and costs will be split equally, with existing Dupixent terms unchanged.

Sanofi and Regeneron collaborate on four new antibodies, similar to Dupixent. Sanofi pays $1 billion upfront, with additional milestone payments tied to clinical and regulatory success. The companies will split costs and profits evenly, excluding existing Dupixent profits.

Sanofi and Regeneron expanded their collaboration with an $80B deal, including a $10B upfront payment. They will develop four new antibody therapies for inflammatory diseases. Regeneron will handle development, while Sanofi manages global sales. Regeneron's stock is considered 16.4% undervalued with a GF Score of 88/100, indicating strong financial health and growth potential.

Regeneron's experimental weight-loss drug, combined with Novo Nordisk's semaglutide, reduced muscle mass loss by 50% in a study. The trial involved patients using both drugs.

Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance, targeting type 2 inflammation with four antibodies. Regeneron will receive $1B upfront and up to $7B in milestones. They will share development costs and profits equally. The deal builds on their 20-year collaboration, including Dupixent, used by 1.5M patients.